Literature DB >> 12558826

The natural history of epilepsy in the era of new antiepileptic drugs and surgical treatment.

J W Sander1.   

Abstract

PURPOSE: To review the factors influencing prognosis of epilepsy in this era of antiepileptic drugs and surgical treatment.
METHODS: Systematic review of peer-reviewed literature.
RESULTS: The prognosis depends on many factors; aetiology, age of onset, number of seizures at onset, the natural history of the condition, and the influence of treatment. However, between 70 and 80% of people developing epilepsy will go into long-term remission, usually within the first 5 years. DISCUSSION: Prognosis in epilepsy is the prospect of attaining complete seizure freedom once a pattern of recurrent epileptic seizures has been established. Well-designed prospective cohort studies using standard outcome measures need to be conducted, especially in non-Western cultures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558826     DOI: 10.1046/j.1528-1157.44.s.1.1.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Optical control of focal epilepsy in vivo with caged γ-aminobutyric acid.

Authors:  Xiaofeng Yang; Daniel L Rode; Darcy S Peterka; Rafael Yuste; Steven M Rothman
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

2.  Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery.

Authors:  Nasir Mirza; Olga Vasieva; Anthony Guy Marson; Munir Pirmohamed
Journal:  Hum Mol Genet       Date:  2011-08-18       Impact factor: 6.150

3.  Epilepsy: The future scenario.

Authors:  H V Srinivas
Journal:  Ann Indian Acad Neurol       Date:  2010-01       Impact factor: 1.383

4.  Genetic regulation of gene expression in the epileptic human hippocampus.

Authors:  Nasir Mirza; Richard Appleton; Sasha Burn; Daniel du Plessis; Roderick Duncan; Jibril Osman Farah; Bjarke Feenstra; Anders Hviid; Vivek Josan; Rajiv Mohanraj; Arif Shukralla; Graeme J Sills; Anthony G Marson; Munir Pirmohamed
Journal:  Hum Mol Genet       Date:  2017-05-01       Impact factor: 6.150

5.  COVID-19 pandemic influence on epilepsy course in pediatric patients.

Authors:  Karolina Anuszkiewicz; Piotr Stogowski; Marta Zawadzka; Przemysław Waszak; Ewa Sokolewicz; Natalia Aleksandra Dułak; Kamil Dzwilewski; Karolina Jażdżewska; Kamila Karbowiak; Daria Karlińska; Anna Marczak; Anna Niebrzydowska; Bartosz Niebrzydowski; Ewa Pasierbska; Agnieszka Sadowska; Małgorzata Szczęsna; Piotr Stanisław Szczęsny; Anna Szerszenowicz; Kamil Sztramski; Jakub Radziwon; Magdalena Tkaczuk; Kinga Ziołkowska; Maria Mazurkiewicz-Bełdzińska
Journal:  Epilepsy Behav       Date:  2022-01-24       Impact factor: 3.337

6.  Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study.

Authors:  Irawan Mangunatmadja; Raden Muhammad Indra; Dwi Putro Widodo; Achmad Rafli
Journal:  Behav Neurol       Date:  2021-11-10       Impact factor: 3.342

7.  Clinical value of lncRNA TUG1 in temporal lobe epilepsy and its role in the proliferation of hippocampus neuron via sponging miR-199a-3p.

Authors:  Chunlian Li; Xiaojing Zheng; Pingping Liu; Meilian Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Seizure control of current shunt on rats with temporal lobe epilepsy and neocortical epilepsy.

Authors:  Limin Zhang; Shuli Liang; Guojun Zhang; Zhizhong Liu; Hong Lv; Fang Fang; Yajie Wang; Shaohui Zhang; Xixiong Kang
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

9.  A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.

Authors:  Uwe Runge; Stephan Arnold; Christian Brandt; Fritjof Reinhardt; Frank Kühn; Kathleen Isensee; Francisco Ramirez; Peter Dedeken; Thomas Lauterbach; Matthias Noack-Rink; Thomas Mayer
Journal:  Epilepsia       Date:  2015-11-03       Impact factor: 5.864

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.